| Dr Chad Seymour Lewis, MD | |
|
18524 N 94th St, Scottsdale, AZ 85255-2493 | |
| (718) 757-4758 | |
| Not Available |
| Full Name | Dr Chad Seymour Lewis |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 21 Years |
| Location | 18524 N 94th St, Scottsdale, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275713703 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 37717 (Arizona) | Primary |
| 207P00000X | Emergency Medicine | 246764 (New York) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Banner Desert Medical Center | Mesa, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cep America- Arizona, Pc | 1850541970 | 58 |
News Archive
Massachusetts' Institute of Technology (MIT) at its Computer Science and Artificial Intelligence Laboratory (CSAIL) has developed a device that can monitor patients with the highly infective COVID-19 remotely and thus prevent the spread of the infection to healthcare workers.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.
In a new breakthrough British scientists have discovered a "rogue gene" which helps cancer spread around the body and add that this could mean specific therapy, if developed against the gene, could stop cancer spread.
Most paediatricians in Flanders, Belgium, favour the legalisation of lethal drugs to end the life of some critically ill babies and infants, concludes a study in this week's issue of The Lancet.
› Verified 4 days ago
| Entity Name | Banner Hospital Based Physicians Arizona Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275889891 PECOS PAC ID: 3274782487 Enrollment ID: O20121003000752 |
News Archive
Massachusetts' Institute of Technology (MIT) at its Computer Science and Artificial Intelligence Laboratory (CSAIL) has developed a device that can monitor patients with the highly infective COVID-19 remotely and thus prevent the spread of the infection to healthcare workers.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.
In a new breakthrough British scientists have discovered a "rogue gene" which helps cancer spread around the body and add that this could mean specific therapy, if developed against the gene, could stop cancer spread.
Most paediatricians in Flanders, Belgium, favour the legalisation of lethal drugs to end the life of some critically ill babies and infants, concludes a study in this week's issue of The Lancet.
› Verified 4 days ago
| Entity Name | Cep America- Arizona, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780202804 PECOS PAC ID: 1850541970 Enrollment ID: O20121026000403 |
News Archive
Massachusetts' Institute of Technology (MIT) at its Computer Science and Artificial Intelligence Laboratory (CSAIL) has developed a device that can monitor patients with the highly infective COVID-19 remotely and thus prevent the spread of the infection to healthcare workers.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.
In a new breakthrough British scientists have discovered a "rogue gene" which helps cancer spread around the body and add that this could mean specific therapy, if developed against the gene, could stop cancer spread.
Most paediatricians in Flanders, Belgium, favour the legalisation of lethal drugs to end the life of some critically ill babies and infants, concludes a study in this week's issue of The Lancet.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Chad Seymour Lewis, MD 18524 N 94th St, Scottsdale, AZ 85255-2493 Ph: (718) 757-4758 | Dr Chad Seymour Lewis, MD 18524 N 94th St, Scottsdale, AZ 85255-2493 Ph: (718) 757-4758 |
News Archive
Massachusetts' Institute of Technology (MIT) at its Computer Science and Artificial Intelligence Laboratory (CSAIL) has developed a device that can monitor patients with the highly infective COVID-19 remotely and thus prevent the spread of the infection to healthcare workers.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.
In a new breakthrough British scientists have discovered a "rogue gene" which helps cancer spread around the body and add that this could mean specific therapy, if developed against the gene, could stop cancer spread.
Most paediatricians in Flanders, Belgium, favour the legalisation of lethal drugs to end the life of some critically ill babies and infants, concludes a study in this week's issue of The Lancet.
› Verified 4 days ago
Mark A. Tosca, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 8401 E Bonnie Rose Ave, Scottsdale, AZ 85250 Phone: 480-612-1427 Fax: 602-288-2495 | |
Dr. Gregory Walter Schweitz, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 7400 E Osborn Rd, Scottsdale, AZ 85251 Phone: 480-882-4809 | |
Dr. Wyatt Decker, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 480-301-8000 | |
Joshua Lewis, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 8818 E Dahlia Dr, Scottsdale, AZ 85260 Phone: 602-790-6363 | |
Dr. Dustin Gregory Leigh, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 480-301-8000 | |
Dr. Shari Brand, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 480-301-8000 | |
Dr. Kevin M Drechsel, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 480-301-8000 |